TCGA-A2-A3XY-01A-11R-A239-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 36
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.550
- IL6_JAK_STAT3_SIGNALING+0.480
- ALLOGRAFT_REJECTION+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- INTERFERON_ALPHA_RESPONSE+0.460
- INFLAMMATORY_RESPONSE+0.450
- INTERFERON_GAMMA_RESPONSE+0.450
- MYC_TARGETS_V2+0.380
- WNT_BETA_CATENIN_SIGNALING+0.380
- ANGIOGENESIS+0.340
Top 10 suppressed
- PROTEIN_SECRETION-0.500
- ESTROGEN_RESPONSE_EARLY-0.390
- ANDROGEN_RESPONSE-0.310
- PEROXISOME-0.240
- ESTROGEN_RESPONSE_LATE-0.230
- OXIDATIVE_PHOSPHORYLATION-0.210
- BILE_ACID_METABOLISM-0.190
- PI3K_AKT_MTOR_SIGNALING-0.190
- DNA_REPAIR-0.160
- FATTY_ACID_METABOLISM-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-S3-AA15-01A-11R-A41B-07 | — | D | 0.891 |
| 2 | 20050166.TNBC | — | D | 0.883 |
| 3 | TCGA-AC-A8OQ-01A-11R-A41B-07 | — | D | 0.848 |
| 4 | TCGA-B6-A400-01A-11R-A239-07 | — | E | 0.843 |
| 5 | TCGA-OL-A66I-01A-21R-A29R-07 | — | D | 0.827 |
| 6 | TCGA-E9-A1NC-01A-21R-A26B-07 | — | E | 0.815 |
| 7 | TCGA-A7-A6VY-01A-12R-A33J-07 | — | E | 0.812 |
| 8 | R317 | — | — | 0.811 |
| 9 | TCGA-A7-A4SE-01A-11R-A266-07 | — | E | 0.807 |
| 10 | 20050099.TNBC | — | D | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.550 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |